摘要
目的探讨反应停治疗多发性骨髓瘤(multiplemyeloma,MM)的初步疗效。方法11例MM患者,应用反应停起始剂量50mg/d～200mg/d,每2周增加50mg/d～200mg/d直到患者不能耐受。根据患者情况决定伍用化疗。据血M蛋白减少情况判断疗效,分为完全缓解(completeremission,CR)、接近完全缓解(nearlycompleteremissionNCR)、很好的部分缓解(verygoodpartialresponse,VGPR)、部分缓解(partialresponse,PR)、微小反应(minimalresponse,MR)和无反应(non-response,NR)。同时观察贫血、骨髓浆细胞百分比和其他指标的变化。结果NCR3例,VGPR2例,PR5例,总有效率为90.9%。无不能耐受的毒副作用。结论反应停可作为初发或难治MM的治疗选择。
Objective To report the preliminary result of therapy with thalidomide in 11 cases of multiple myeloma(MM) patients. Methods The initial dose of thalidomide was administered from 50mg/d to 200mg/d, then increased 50mg/d to 200mg/d every two weeks until the patient's maximal tolerance. Chemotherapy was accompanied in some patients. The effects were divided as CR, NCR,VGPR, PR, MR and NR. Degree of anemia, percentage of bone marrow plasma cells and other items such as oral ulcer,etc. were observed simultaneously. Results Three cases of patients had NCR, two had VGPR and five had PR. No un-tolerable side effect was found. Conclusions Thalidomide can be used for treatment in the initial or the refractory cases of MM.
出处
《老年医学与保健》
CAS
2002年第4期229-231,共3页
Geriatrics & Health Care
